What medication adjustments are recommended for a patient with major depressive disorder, Alzheimer's disease, obstructive sleep apnea, obesity, lymphedema, congestive heart failure, chronic obstructive pulmonary disease, worsening breast cancer, and anxiety, who is currently taking lisinopril, senna, duloxetine 60 mg daily, melatonin 3 mg at bedtime, acetaminophen 650 mg twice daily, insulin 5 U twice daily, oxycodone 10 mg twice daily, furosemide 40 mg daily, buspirone 7.5 mg twice daily, and lorazepam 0.5 mg as needed every 4 hours, and continues to experience nighttime panic attacks?

Medication Recommendations for Refractory Nighttime Anxiety in Advanced Cancer Patient

Add gabapentin 100-300 mg at bedtime and titrate upward, while simultaneously discontinuing lorazepam through a gradual taper, given the critical respiratory risks in this patient with OSA, COPD, and CHF. 1, 2

Critical Safety Concerns

This patient is at extreme risk for respiratory depression and death from the current medication regimen. The combination of oxycodone (opioid) and lorazepam (benzodiazepine) in a patient with OSA and COPD creates a potentially fatal scenario 2, 3. The FDA explicitly warns that concomitant use of benzodiazepines and opioids can result in profound sedation, respiratory depression, coma, and death 2. In patients with compromised respiratory function (COPD, OSA), lorazepam should be used with extreme caution 2.

The nighttime panic attacks may actually represent nocturnal hypoxia or respiratory distress being misinterpreted as anxiety, particularly given the OSA and COPD. The screaming and fear of not breathing could be actual respiratory compromise rather than pure panic disorder.

Immediate Action Plan

Step 1: Address Potential Neuropathic Cancer Pain Component

The patient's anxiety appears refractory to both opioids and benzodiazepines, suggesting the underlying pain may have a neuropathic component that requires coanalgesic therapy. Cancer pain guidelines specifically recommend anticonvulsants as first-line coanalgesics for neuropathic cancer pain 1.

Start gabapentin:

• Initial dose: 100-300 mg at bedtime (lower end given age, multiple comorbidities, and renal considerations with CHF) 1
• Titration: Increase by 50-100% every few days as tolerated, slower given elderly/medically frail status 1
• Target: 900-1800 mg daily in divided doses (lower than typical maximum given comorbidities)
• Advantages: Addresses neuropathic pain, provides anxiolytic effects, promotes sleep, minimal respiratory depression, and can be dosed primarily at night 1

Step 2: Taper and Discontinue Lorazepam

Benzodiazepines are contraindicated in this clinical scenario due to:

• Respiratory depression risk with OSA/COPD 2, 3
• Synergistic respiratory depression with oxycodone 2
• Cognitive impairment in Alzheimer's disease
• Increased fall/fracture risk with obesity and lymphedema
• Paradoxical agitation possible in elderly 2

Taper schedule (example - adjust based on response):

• Week 1-2: Reduce to 0.25 mg q4h prn
• Week 3-4: Reduce to 0.25 mg q6h prn
• Week 5-6: Reduce to 0.25 mg q8h prn
• Week 7+: Discontinue

Monitor closely for withdrawal symptoms (anxiety, tremor, seizures) 2. The gabapentin will help mitigate withdrawal anxiety.

Step 3: Optimize Existing Duloxetine

The patient is already on duloxetine 60 mg daily, which is appropriate for both depression and potential neuropathic pain 1, 4. Guidelines support increasing duloxetine to 60-120 mg daily for pain management 1. Consider increasing to 90 mg daily after gabapentin is established, as this may provide additional benefit for both mood and pain without the risks of adding another sedating agent.

Step 4: Reassess Oxycodone Dosing

Once gabapentin is at therapeutic levels (typically 2-4 weeks), reassess whether oxycodone dose can be reduced, as the coanalgesic approach may provide better pain control with lower opioid requirements, thereby reducing respiratory depression risk 1.

Alternative Considerations if Gabapentin Insufficient

If gabapentin at therapeutic doses (with adequate trial of 4-6 weeks) does not control symptoms:

Pregabalin as alternative:

• More predictable absorption than gabapentin 1
• Start 25-50 mg at bedtime (lower than standard due to comorbidities)
• Titrate to 50-75 mg twice daily
• Requires renal dose adjustment (important with CHF/Lasix use) 1

Low-dose mirtazapine (15 mg at bedtime):

• More sedating at lower doses
• Addresses depression, anxiety, and insomnia
• Minimal respiratory depression
• May stimulate appetite (consider given cancer cachexia)
• However, avoid if patient already has excessive sedation

What NOT to Do

Do not increase buspirone - already on 7.5 mg BID, and buspirone has limited efficacy for acute panic attacks and no role in cancer pain management.

Do not add antipsychotics (quetiapine, olanzapine) - while mentioned in insomnia guidelines 5, they carry significant risks in this patient: metabolic effects with obesity/diabetes, increased mortality in dementia patients, and sedation compounding respiratory risks.

Do not use tricyclic antidepressants - despite their efficacy for neuropathic pain 1, 4, the anticholinergic effects are contraindicated in Alzheimer's disease and pose cardiac risks with CHF 4.

Non-Pharmacologic Interventions

Essential psychosocial support per cancer pain guidelines 1:

• Provide emotional support acknowledging the pain and anxiety
• Ensure staff availability and reassurance (the patient's request for staff presence is legitimate and therapeutic)
• Educate patient and family that emotional reactions to pain are normal
• Consider palliative care consultation for advanced cancer with multiple comorbidities 6

Environmental modifications:

• Elevate head of bed for OSA/CHF
• Ensure CPAP compliance if prescribed
• Nightlight and call bell within reach
• Scheduled nighttime checks rather than prn only

Monitoring Plan

• Weekly assessment initially: pain scores, anxiety levels, respiratory status, sedation level
• Monitor for gabapentin side effects: dizziness, sedation, peripheral edema (concerning with existing CHF/lymphedema)
• Renal function monitoring: gabapentin requires dose adjustment with renal impairment; CHF and Lasix increase this risk 1
• Reassess lorazepam taper: watch for withdrawal symptoms
• Oxygen saturation monitoring: given OSA/COPD and medication changes

Key Pitfall to Avoid

The most dangerous pitfall is continuing or escalating benzodiazepines in a patient already on opioids with severe respiratory comorbidities. This combination has killed patients 2. The anxiety may actually improve once the respiratory-depressing medications are reduced and the underlying neuropathic pain is better controlled with appropriate coanalgesics.